扎那米韦治疗甲型流感临床研究进展
Progress in Clinical Studies of Zanamivir in the Treatment of Influenza A

甲型流感病毒因其高变异性和传播能力，能够引起全球性的大流行。目前，抗流感病毒药物是临床治疗流感的主要手段，这些药物通过阻断病毒的进入、复制和释放等环节发挥抗病毒作用。然而，流感病毒的变异和逃避免疫系统的能力促使科研人员不断分析新的甲型流感抗病毒药物。扎那米韦是一种有效的神经氨酸酶抑制剂，通过抑制病毒从宿主细胞中释放，从而限制其在体内的传播。随着流感病毒的不断变异和耐药性的增加，单一药物的治疗方案已经不足以应对当前的流感挑战。因此，开发与扎那米韦等神经氨酸酶抑制剂联合使用，成为当前抗流感药物研发的热点。本文综述了扎那米韦在治疗甲型流感方面的临床研究进展，重点关注了其对流感治疗作用，期望对流感临床药学应用发展提供新的用药治疗参考。
Influenza A viruses are capable of causing a global pandemic due to their high mutability and transmissibility. Currently, anti-influenza virus drugs are the mainstay of clinical treatment for influenza, and these drugs exert their antiviral effects by blocking the entry, replication, and release of the virus. However, the ability of influenza viruses to mutate and evade the immune system has prompted researchers to continuously analyze new influenza A antiviral drugs. Zanamivir is a potent neuraminidase inhibitor that works by inhibiting the release of the virus from host cells, thereby limiting its spread through the body. As influenza viruses continue to mutate and increase drug resistance, single-drug regimens are no longer sufficient to meet the current influenza challenge. Therefore, the development of combinations with neuraminidase inhibitors, such as zanamivir, has become a hot topic in current anti-influenza drug development. This article reviews the clinical research progress of zanamivir in the treatment of influenza A, focusing on its therapeutic effect on influenza, and expects to provide new references for the development of influenza clinical pharmacy applications for drug therapy.